← All trials
NCT02036164
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 1, 2014
- Primary completion
- Jan 1, 2018
- Completion date
- Jan 1, 2019
- First posted
- —
- Last posted
- —
- Enrollment
- 500
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Navamindradhiraj UniversityLead sponsor
- Navamindradhiraj UniversityOverall official - principal investigator
- Navamindradhiraj UniversitySponsor investigator
- Navamindradhiraj UniversityCollaborator
- Prince of Songkla UniversityCollaborator
- National Research Council of ThailandCollaborator
- Bhumibol Adulyadej HospitalCollaborator
- Lopburi Cancer HospitalCollaborator
- Ubonratchathani Cancer HospitalCollaborator
- Chonburi Cancer HospitalCollaborator
- Lampang Cancer HospitalCollaborator
- Rajburi HospitalCollaborator
- KhonKaen UniversityCollaborator
- Chiangmai UniversityOverall official - principal investigator
- Chiangmai UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.